secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107295
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Fractyl Health Q2 2025 net loss $27.9M; $23M offering extends cash runway into 2026
--------------------------------------------------------------------------------

- Net loss for Q2 2025 was $27.9 million, compared to $17.2 million in Q2 2024, driven by higher R&D spending and non-cash changes.
- Completed $23 million underwritten public offering in August 2025, with potential additional $46 million from warrants.
- Cash and cash equivalents were $22.3 million as of June 30, 2025; post-offering cash runway extends into 2026.
- Positive 3-month REVEAL-1 Cohort data: 12 of 13 participants maintained weight after GLP-1 discontinuation with Revita.
- Enrollment completed for REMAIN-1 Midpoint Cohort (45 participants); 3-month randomized data expected September 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025107295/0000950170-25-107295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025107295/guts-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer